Related Experiment Video
Updated: Jul 20, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Novel targets in prostate cancer.
Dominik R Berthold1, Malcolm J Moore
1Princess Margaret Hospital and University of Toronto, Department of Medical Oncology and Hematology, 610 University Avenue Toronto, Ontario M5G 2M9, Canada. dominik.berthold@uhn.on.ca
Expert Opinion on Therapeutic Targets
|September 20, 2006
Summary
New prostate cancer treatments are emerging. Research presented at ASCO 2006 explored novel targets, vitamin D and chemotherapy combinations, and the effects of targeted therapy sorafenib.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Research
Background:
- Despite advances in prostate cancer biology, novel treatment options remain limited.
- Targeted therapies offer promise for solid tumors, driving clinical research in advanced prostate cancer.
Framework:
- ASCO 2006 symposium focused on novel prostate cancer targets.
- Presentations included androgen receptor quantification, vitamin D/chemotherapy impact, and sorafenib effects.
Implementation:
- A new method for androgen receptor quantification was discussed.
- The impact of high-dose vitamin D plus chemotherapy on hormone-refractory prostate cancer and thromboembolic disease risk was evaluated.
- Paradoxical effects of sorafenib (VEGF/raf-kinase inhibitor) were observed, including bone scan improvements without PSA response.
Implications:
- Findings highlight diverse research avenues for advanced prostate cancer.
- Exploration of novel targets and combination therapies is crucial.
- Understanding paradoxical drug effects like those of sorafenib is key for future treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...